The global pulmonary hypertension (PH) drug market, valued at $7.2B in 2025 and growing at a 5.3% CAGR, relies heavily on vasodilators like Johnson & Johnson's Uptravi and Merck's Adempas, which manage symptoms but require lifelong use. Pulnovo's PADN (Pulmonary Artery Denervation) system, a one-time catheter-based radiofrequency ablation procedure, targets sympathetic nerves around the pulmonary artery to reduce pressure—offering a potential durable alternative. Medtronic's investment signals a strategic pivot toward interventional cardiology devices, where it lags behind Abbott and Boston Scientific in PH innovation.
Deal Structure and Competitive Implications
Medtronic led the oversubscribed $100M round, likely securing exclusive rights to distribute PADN in key markets—a common move in medtech strategic deals. Pulnovo's valuation post-money is estimated at $500M-$600M, based on comparable transactions like Shockwave Medical's $13.1B acquisition by J&J in 2023. This positions Pulnovo ahead of peers such as Aerovate Therapeutics, whose inhaled drug AV-101 failed a Phase 2b trial in 2024, highlighting the risk in drug-based PH approaches. Pulnovo's PADN catheter is already NMPA/CE-approved in China/EU, with U.S. trials under FDA HUD/IDE designation, accelerating a 2028-2030 launch timeline.
Device-based therapies like PADN could capture 20-30% of the PH market by 2030, driven by superior cost-effectiveness over chronic drugs.
Pipeline and Clinical Roadmap
Pulnovo's lead asset, the PADN Catheter Series, targets PH Groups I, II, and IV, with ongoing trials including PADN-COLUMBUS in Europe for Group II PH. The company's PFlexi Steerable Sheath and PHD360 RF Ablation Generator, both FDA/NMPA-approved, support procedure adoption. Upcoming data from the PADN for PH-HF trial in China, expected in late 2026, will be critical for demonstrating efficacy in heart failure patients—a population where drug options are limited. The Enhancor Series, in NMPA innovation review, hints at future cardiopulmonary expansions.
For investors, Pulnovo represents a leveraged play on PH market disruption, with Medtronic's backing de-risking commercial execution. Key catalysts include U.S. trial initiations in 2026 and potential CE mark expansions in Europe. Risks include regulatory delays and competition from Abbott's CardioMEMS HF system, which monitors but doesn't treat PH. If PADN achieves 15% penetration in addressable PH patients (~500,000 globally), it could generate $1.5B in peak sales, justifying current valuation multiples.
